Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133,…
| Price | $100.76 |
|---|---|
| Market cap | $6.56B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | NASDAQ |
| 52-week range | 49.67-111.86 |
| Beta | -0.06 |
Explore LNTH's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.